Venus Medtech (Hangzhou), Inc. Class H 2500

Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The completion of enrollment marks a major milestone toward European regulatory approval for Cardiovalve's Transcatheter Tricuspid Valve Replacement (TTVR) system, the company's flagship solution for treating tricuspid regurgitat